U.S. Granted Patent 8,088,385 B2 Strengthens Advanced Cardiac Therapeutics' Anti-Cancer Product Portfolio
4/3/2012 9:48:51 AM
LOUISVILLE, Ky., April 3, 2012 (GLOBE NEWSWIRE) -- Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced that it has been granted U.S. Patent 8,088,385 B2 titled "PFKFB3 inhibitor for the treatment of a Proliferative Cancer" by the United States Patent Office. ACT is the exclusive licensee to this issued patent that was initially filed by the University of Louisville Research Foundation.
comments powered by